Instilación intrapleural de activador tisular de plasminógeno y de deoxirribonucleasa recombinante humana en el empiema pleural. Visits. Download PDF. Se colocó un catéter en el extremo aórtico de la fístula y se instauró, a su través, tratamiento con activador recombinante tisular del plasminógeno (r-TPA) en. activator in vascular warning syndromesTrombólisis intravenosa con activador tisular del plasminógeno recombinante en los síndromes de alarma vascular☆.

Author: Tor Kazira
Country: Cyprus
Language: English (Spanish)
Genre: Environment
Published (Last): 20 June 2008
Pages: 36
PDF File Size: 20.45 Mb
ePub File Size: 14.77 Mb
ISBN: 817-1-66054-564-2
Downloads: 66291
Price: Free* [*Free Regsitration Required]
Uploader: Kikazahn

The journal fully endorses the goals of updating knowledge and facilitating the acquisition of key developments in internal medicine applied to clinical practice.

There was a problem providing the content you requested

To improve our services and products, we use “cookies” own or third parties authorized to show advertising related to client preferences through the analyses of navigation customer behavior. They received between 1 to 5 cycles with rTPA.

Are you a health professional able to prescribe or dispense drugs? From Monday to Friday from 9 a.

Activador del plasminógeno tisular recombinante en el manejo de trombos cardiacos en recién nacidos

Si continua navegando, consideramos que acepta su uso. SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field. Previous article Next article. CiteScore measures average citations received per document published.


The superior vena cava was the most frequent location, with a mean plasminogenp of installation before the diagnosis of 12 days. You can change the settings or obtain more information by clicking here. Subscribe to our Newsletter. Four patients had intracranial haemorrhage grade I, without sequelae at follow-up. In 4 patients complete resolution of the thrombus was achieved in a mean of 3.

Thrombolysis with recombinant tissue plasminogen activator rTPA has been used as an alternative to heparin in life threatening giant thrombus and embolization.

Print Send to a friend Export reference Mendeley Statistics.

Intracardiac thrombi; Neonatal thrombolysis; Recombinant tissue plasminogen activator. The aim of this study is to describe the response and complications related to the use of rTPA in the management of life- threatening cardiac thrombi in newborns.

March Pages ee24 Pages There were no deaths or embolism. Recombinant tissue plasminogen activator for the management of intracardiac thrombi in newborns. This item has received. The medical records of 8 newborn were reviewed in a retrospective study, plasminogfno whom 7 were preterm with cardiac thrombi, and rTPA was used in all of them. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal’s impact.


Continuing navigation will be considered as acceptance of this use. Nine issues are published activaxor year, including mostly originals, reviews and consensus documents. The patients included 4 males with a mean weight of gr. SRJ is a prestige metric based on the idea that not all citations are the same.

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two receding years. The incidence of cardiac thrombi in newborns has increased with the use of central venous catheters.

Subscriber If you already have your login data, please click here. Three patients received low molecular weight heparin prior to using rTPA.